Brilaroxazine lipogel displays antipsoriatic activity in imiquimod‐induced mouse model
Open Access
- 16 February 2024
- journal article
- research article
- Published by Wiley in Skin Research and Technology
- Vol. 30 (2) , e13606
Abstract
Background: Dopamine (D) and serotonin (5‐HT) pathways contribute to psoriasis pathobiology. Disruptions incite increased inflammatory mediators, keratinocyte activation and deterioration, and worsening symptoms. Brilaroxazine (RP5063), which displays potent high binding affinity to D 2/3/4 and 5‐HT 1A/2A/2B/7 receptors and a moderate affinity to serotonin transporter (SERT), may affect the underlying psoriasis pathology. Methods: An imiquimod‐induced psoriatic mouse model (BALB/c) evaluated brilaroxazine's activity in a topical liposomal‐aqueous gel (Lipogel) formulation. Two of the three groups (n = 6 per) underwent induction with 5% imiquimod, and one group received topical brilaroxazine Lipogel (Days 1–11). Assessments included (1) Psoriasis Area and Severity Index (PASI) scores (Days 1–12), skin histology for Baker score based on H&E stained tissue (Day 12), and serum blood collection for serum cytokine analysis (Day 12). One‐way ANOVA followed by post hoc Dunnett's t ‐test evaluated significance ( p < 0.05). Results: Imiquimod‐induced animal Baker scores were higher versus Sham non‐induced control's results ( p < 0.001). Brilaroxazine Lipogel had significantly ( p = 0.003) lower Baker scores versus the induced Psoriasis group. Brilaroxazine PASI scores were lower ( p = 0.03) versus the induced Psoriasis group (Days 3‐12), with the greatest effect in the last 3 days. The induced Psoriasis group showed higher Ki‐67 and TGF‐β levels versus non‐induced Sham controls ( p = 0.001). The brilaroxazine Lipogel group displayed lower levels of these cytokines versus the induced Psoriasis group, Ki‐67 ( p = 0.001) and TGF‐β ( p = 0.008), and no difference in TNF‐α levels versus Sham non‐induced controls. Conclusion: Brilaroxazine Lipogel displayed significant activity in imiquimod‐induced psoriatic animals, offering a novel therapeutic strategy.Keywords
This publication has 49 references indexed in Scilit:
- Nature of cell kinetics in psoriatic epidermisJournal of Cutaneous Pathology, 2007
- Expression of serotonergic receptors in psoriatic skinArchives of Dermatological Research, 2006
- Measuring quality of life of patients with different clinical types of psoriasis using the SF-36British Journal of Dermatology, 2006
- Dopamine by itself activates either D2, D3 or D1/D5 dopaminergic receptors in normal human T-cells and triggers the selective secretion of either IL-10, TNFα or bothJournal of Neuroimmunology, 2005
- Dopamine D2-Like Receptor Agonists Accelerate Barrier Repair and Inhibit the Epidermal Hyperplasia Induced by Barrier DisruptionJournal of Investigative Dermatology, 2005
- The Development and Characterization of an In Vitro Model of PsoriasisJournal of Investigative Dermatology, 2004
- Expression of serotonin receptors in allergic contact eczematous human skinArchives of Dermatological Research, 2002
- The role of stress in the pathophysiology of the dopaminergic systemMolecular Psychiatry, 2000
- The relationship of Ki67 and involucrin expression in proliferative, pre-neoplastic and neoplastic skinClinical and Experimental Dermatology, 1997
- Ki67—Structure, function, and new antibodiesThe Journal of Pathology, 1992